Search results
Order by most recent / most popular / relevance
Results: 1-10 of 43
Pfizer v. Apotex, PMNOC Regulations decision
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- May 21 2010
Apotex alleged in its NOA that Pfizer's patent was invalid for double patenting, anticipation, obviousness, lack of utility and over-breadth
Novo Nordisk v. Cobalt Pharmaceuticals, S. 55.2 proceeding, Repaglinide, Aug. 3, 2010
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- August 26 2010
Cobalt served a NOA with respect to repaglinide, the S enantiomer of a previously disclosed racemic compound (the “388 compound”), alleging invalidity of the '851 patent on grounds of anticipation, obviousness and s. 53(1
Pfizer v Ratiopharm, appeal of decision on invalidity, Amlodipine Besylate, July 29, 2010
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- August 26 2010
In the Federal Court, Pfizer's patent for amlodipine besylate was held invalid on numerous grounds, including obviousness
Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- October 27 2010
This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998
AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- May 21 2010
AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing
Janssen v Mylan, unsuccessful PMNOC proceedings, galantamine, November 11, 2010
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- November 24 2010
Janssen sought an order of prohibition until expiry of its '950 patent which claimed the use of an optimum dosing regimen of galantamine to treat Alzheimer's Disease
Apotex loses the war in Canada and the battle in England: UK courts rely on Canadian decision to find Apotex acting unlawfully in cCnada has consequences in eErope
- Gowling Lafleur Henderson LLP
- -
- Canada, United Kingdom
- -
- October 13 2011
Servier developed perindopril erbumine (“perindopril”) which is a successful long lasting ACE inhibitor sold under the trade-mark COVERSYL
Merck-Frosst-Schering Pharma GP v. Canada (Health) (2010 FC 933)
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- October 27 2010
Merck-Frosst (“Merck”) applied for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Teva for its generic version of Ezetimibe
Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- May 21 2010
The Supreme Court of Canada has granted Celgene Corporation's application for leave to appeal the decision of a majority of the Federal Court of Appeal regarding the jurisdiction of the Patented Medicine Prices Review Board
Pfizer v. Novopharm, interlocutory motion in PMNOC Regulations case
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- May 21 2010
Novopharm served a NOA on Pfizer which it had designated confidential
Current Search
- Workarea - Healthcare
- Jurisdiction - Canada
- Author - Scott Foster